Loading...
OTCM
GTHP
Market cap24mUSD
Jul 10, Last price  
0.30USD
1D
14.29%
1Q
46.79%
Jan 2017
-40.59%
Name

Guided Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:GTHP chart
P/E
—
P/S
30.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
48.75%
Rev. gr., 5y
49.71%
Revenues
767k
+10,857.14%
977,0001,037,0001,317,0001,550,0003,364,0003,597,0003,410,0001,179,000823,000606,000605,000244,00057,00036,000102,00081,00013,00098,0007,000767,000
Net income
-3m
L+32.23%
-4,948,0003,016,000-4,810,000-6,212,000-2,846,000-6,644,000-4,353,000-7,215,000-9,883,000-6,902,000-3,970,000-10,696,0001,016,000-1,921,000-279,000-2,070,000-4,341,000-3,489,000-2,417,000-3,196,000
CFO
-1m
L-4.56%
-3,575,000-3,944,000-1,909,000-1,420,000-347,000-2,734,000-3,666,000-5,556,000-6,283,000-4,043,000-1,802,000-1,144,000-1,365,000-806,000-1,875,000-1,592,000-1,478,000-1,746,000-1,119,000-1,068,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.
URL
https://www.guidedinc.com/
IPO date
Jul 01, 1997
Employees
6
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT